New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...
February 17, 2026 / Sciad Communications / Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, ...
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...
Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...
SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
Cassava (Manihot esculenta Crantz, 2n = 36) is one of the most important root crops globally, particularly in tropical regions of Africa, Asia, and Latin America. It is a major source of food, ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results